Full-Time

Associate Director – Commercial IT Data and Analytics Lead

Posted on 1/29/2025

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$195k - $250kAnnually

Senior, Expert

San Francisco, CA, USA

Hybrid position requiring some in-office days.

Category
Data Management
Data Analysis
Data & Analytics
Required Skills
Power BI
Talend
Microsoft Azure
Python
R
SQL
SAP Products
Tableau
AWS

You match the following BridgeBio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree in Computer Science, Information Technology, Data Science, or a related field; Master’s degree preferred
  • 7+ years in data architecture, data engineering, or a related role, with experience in a commercial IT environment within the life sciences or biotech/pharma industry
  • Strong understanding of commercial operations within life sciences, including tools like Veeva CRM, Veeva Network, SAP, and other industry-specific tools
  • Comprehensive knowledge of HCP, HCO, Payer, Specialty Pharmacy (SP), Specialty Distributor (SD), 3PL, and Patient data domains
  • Expertise in SQL, data modeling, data warehousing, and data lake architecture. Proficiency in data tools and technologies such as SQL, Python, R, Alteryx, and BI tools including Power BI and Tableau, along with cloud data platforms like AWS and Azure
  • Familiarity with regulatory frameworks (e.g., HIPAA, GDPR, Sunshine Act) governing data use in healthcare
  • Proficiency with ETL tools (e.g., Informatica, Talend), iPaaS platforms (e.g., Workato, MuleSoft, Boomi) and API integrations
  • Analytical mindset, problem-solving aptitude, effective communication, and a collaborative approach to cross-functional engagement
Responsibilities
  • Design a scalable, flexible, and high-performance data architecture to support commercial functions
  • Establish data governance & integration strategies, standards, and best practices, enhancing adaptability for business growth and advanced analytics needs
  • Oversee Master Data Management (MDM) systems housing Healthcare Professionals (HCPs), Healthcare Organizations (HCOs), Integrated Delivery Networks (IDNs), Pharmacies, and Payer data, ensuring data accuracy, consistency, and availability to support commercial operations
  • Oversee the maintenance and optimization of data platforms, including data warehouses, data lakes, and BI tools (e.g., Power BI) supporting analytics and reporting functions
  • Develop and maintain data models for enterprise systems, ensuring consistency and high data quality
  • Drive adherence to data governance practices, securing data integrity, compliance, and usability
  • Lead the creation of robust data integration solutions using ETL tools and APIs, promoting seamless data flow across platforms like Veeva CRM, SAP, and other analytics tools essential to commercial teams
  • Partner with Commercial, Medical, IT, and Analytics teams to capture data requirements and translate business needs into scalable solutions
  • Act as a liaison, facilitating clear communication between technical teams and business stakeholders
  • Drive the development of data solutions that balance strategic vision with practical implementation, fostering collaboration across technical and business teams
  • Manage third-party vendors and service providers, ensuring alignment with BridgeBio’s data strategy and compliance standards
  • Lead vendor selection, contract negotiations, and monitor service-level agreements to ensure optimal performance and service quality
  • Empower commercial teams by promoting self-service analytics and supporting the development of data visualization and reporting solutions
  • Ensure data architecture and processes meet regulatory requirements, including Data Privacy, GDPR, GxP, and SOX, supporting data governance initiatives for Commercial IT

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create therapies that address the genetic roots of diseases, potentially leading to significant improvements in patient health. With over 15 drug programs targeting 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

1%

2 year growth

0%
The Manila Times
Jan 8th, 2025
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.

Access Market Intelligence
Dec 6th, 2024
Orsini and PANTHERx Rare Selected by BridgeBio as Pharmacy Partners for ATTRUBY

PANTHERx Rare, a leader in rare disease product patient access and support services in the United States, also announced that it was selected by BridgeBio for the distribution of Attruby (acoramidis).

PR Newswire
Nov 26th, 2024
Bridgebio Selects Pantherx® Rare Specialty Pharmacy For Distribution Of Attruby™ (Acoramidis)

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by BridgeBio for the distribution of Attruby™ (acoramidis), a high-affinity transthyretin (TTR) stabilizer for twice daily oral administration, approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).2,5. Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby was designed to mimic a naturally occurring "rescue mutation" of the TTR gene (T119M) that targets the root cause of ATTR-CM, destabilization of the native TTR tetramer. Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes. "Panther is committed to providing tailored solutions for people living with rare and devastating conditions and we look forward to the partnership with BridgeBio and serving the needs of patients suffering from transthyretin amyloid cardiomyopathy," said Rob Snyder, Executive Chair, PANTHERx® Rare Pharmacy

MarketBeat
Nov 24th, 2024
Jennison Associates LLC Invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Jennison Associates LLC invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO).

Business Wire
Sep 9th, 2024
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage precision oncology company, has announced the appointment of Yong (Ben) Ben, MD, as Chief Medical and Development Officer.

INACTIVE